Burrill's virtual venture

Burrill's virtual venture

One of the great unmet needs in the biopharmaceutical industry lies in the seemingly endless stretch of time between a company's second or third venture round and the first few years after it has gone public. Between the period when companies can look to their venture backers for help and the time when they near maturity, access to broad managerial expertise and capital can be difficult.

Steven Burrill, who was national director of manufacturing/high technology industry

Read the full 799 word article

How to gain access

Continue reading with a
two-week free trial.